Page last updated: 2024-10-29

imipramine and Fatty Liver

imipramine has been researched along with Fatty Liver in 1 studies

Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liangpunsakul, S1
Rahmini, Y1
Ross, RA1
Zhao, Z1
Xu, Y1
Crabb, DW1

Other Studies

1 other study available for imipramine and Fatty Liver

ArticleYear
Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice.
    American journal of physiology. Gastrointestinal and liver physiology, 2012, Mar-01, Volume: 302, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Ceramides; Enzyme Activation; Ethanol; Fatty

2012